Yvonne Greenstreet, Alnylam CEO (Suzanne Kreiter/The Boston Globe via Getty Images)
Alnylam heralds PhIII APOLLO-B win on way to creating an ‘industry leading TTR franchise’
Alnylam $ALNY has laid claim to a major success in Phase III, with its RNAi drug patisiran hitting the primary endpoint in its APOLLO-B study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
